Brought to you by 
Enanta, Chiron team up a second time for HCV therapeutics
02 Jun 2005
Executive Summary
Enanta Pharmaceuticals (small-molecule anti-infectives) will help Chiron exclusively develop and market its portfolio of protease inhibitors that target enzymes responsible for viral replication of the hepatitis C virus (HCV). Chiron keeps some global (excluding Asia) co-development and marketing rights.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Enanta, Chiron team up a second time for HCV therapeutics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice